Login / Signup

Bioorthogonal Bond Cleavage Chemistry for On-demand Prodrug Activation: Opportunities and Challenges.

Qingqiang MinXingyue Ji
Published in: Journal of medicinal chemistry (2023)
Time- and space-resolved drug delivery is highly demanded for cancer treatment, which, however, can barely be achieved with a traditional prodrug strategy. In recent years, the prodrug strategy based on a bioorthogonal bond cleavage chemistry has emerged with the advantages of high temporospatial resolution over drug activation and homogeneous activation irrespective of individual heterogeneity. In the past five years, tremendous progress has been witnessed in this field with one such bioorthogonal prodrug entering Phase II clinical trials. This Perspective aims to highlight these new advances (2019-2023) and critically discuss their pros and cons. In addition, the remaining challenges and potential strategic directions for future progress will also be included.
Keyphrases
  • cancer therapy
  • clinical trial
  • phase ii
  • drug delivery
  • drug release
  • open label
  • dna binding
  • emergency department
  • current status
  • randomized controlled trial
  • phase iii
  • risk assessment
  • human health
  • adverse drug